Plain-English translation of NCT05508932 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Researchers want to understand why some people with beta-thalassemia develop atrial fibrillation (an irregular heartbeat) while others do not. This is an observational study, meaning researchers will collect information from patients' medical records, heart tests, and blood work over a 10-year period rather than giving a new treatment. The study will also look at whether a class of diabetes medications called SGLT2-inhibitors might help protect the heart in these patients.
People with beta-thalassemia are at higher risk for heart problems, including irregular heartbeats, but doctors don't fully understand why some patients develop these problems and others don't. By comparing patients with and without heart rhythm problems, researchers hope to identify early warning signs and learn whether existing medications might help prevent or manage this complication.
You likely qualify if…
You likely don't qualify if…
You would allow researchers to collect and review your medical information from heart evaluations you have already had (or will have) at the hospital's cardiology unit between 2012 and 2032. This includes your heart test results, blood work, and other health records—no new procedures or medications required. Participation is passive and involves sharing existing medical data to help researchers understand patterns in heart health for people with beta-thalassemia.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Italy
Sponsor
University Hospital of Ferrara
Enrollment target
~350 participants
Started
September 2022
Primary completion
June 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.